Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
Shaochuan Liu, Tingting Qin, Zhujun Liu, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 5
Open Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

Immunomodulation by endothelial cells — partnering up with the immune system?
Jacob Amersfoort, Guy Eelen, Peter Carmeliet
Nature reviews. Immunology (2022) Vol. 22, Iss. 9, pp. 576-588
Open Access | Times Cited: 275
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 527-540
Closed Access | Times Cited: 262
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Tianqing Chu, Runbo Zhong, Hua Zhong, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 4, pp. 643-652
Open Access | Times Cited: 187
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Jamal Majidpoor, Keywan Mortezaee
Clinical Immunology (2021) Vol. 226, pp. 108707-108707
Closed Access | Times Cited: 172
Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies
Raefa Abou Khouzam, Klaudia Brodaczewska, Aleksandra Filipiak-Duliban, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 154
Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications
Jian-Wen Fang, Yue Lu, Jingyan Zheng, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 9
Open Access | Times Cited: 87
Recent progress of carbon dots in targeted bioimaging and cancer therapy
Cheng‐Long Shen, Hang-Rui Liu, Qing Lou, et al.
Theranostics (2022) Vol. 12, Iss. 6, pp. 2860-2893
Open Access | Times Cited: 81
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Shaochuan Liu, Qian Sun, Xiubao Ren
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 49
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 33
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
Robby Barnestein, Loïck Galland, Laura Kalfeist, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 58
The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
Raefa Abou Khouzam, Rania F. Zaarour, Klaudia Brodaczewska, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 52
Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer
Jie Luo, Kebin Cheng, Xianxiu Ji, et al.
Cancer Letters (2024) Vol. 591, pp. 216892-216892
Closed Access | Times Cited: 15
Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application
Anqi Li, Jian‐Hong Fang
Deleted Journal (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 12
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
Xiao Han, Jun Guo, Lingyu Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis
Chi Zhang, Fengtao Wei, Wenhan Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-κB and STAT3 signaling pathways in nasopharyngeal carcinoma
Yan Wang, Yuanyuan Chen, Yuanyuan Liu, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
Xiangyu Zhang, Liang Zeng, Yizhi Li, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 9, pp. 2517-2528
Open Access | Times Cited: 56
The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime
Marco Chilosi, Venerino Poletti, Claudia Ravaglia, et al.
Modern Pathology (2021) Vol. 34, Iss. 8, pp. 1444-1455
Open Access | Times Cited: 49
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
Yongkun Sun, Aiping Zhou, Wen Zhang, et al.
Hepatology International (2021) Vol. 15, Iss. 3, pp. 621-629
Open Access | Times Cited: 46
(Im)maturity in Tumor Ecosystem
Keywan Mortezaee, Jamal Majidpoor
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 33
Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy
Lian Yu, Yaohua Hu, Jianlin Xu, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 3, pp. 635-643
Closed Access | Times Cited: 20
T cell exhaustion in human cancers
Kuan Kang, Xin Lin, Pan Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189162-189162
Closed Access | Times Cited: 8
Anti-lymphangiogenesis for boosting drug accumulation in tumors
Chunling Wang, Junchao Xu, Xiaoyu Cheng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
Sergio Ayala‐Mar, Javier Donoso‐Quezada, José González‐Valdez
Journal of Immunology Research (2021) Vol. 2021, pp. 1-18
Open Access | Times Cited: 41
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study
Na Zhou, Man Jiang, Tianjun Li, et al.
Lung Cancer (2021) Vol. 160, pp. 111-117
Closed Access | Times Cited: 33
Page 1 - Next Page

Scroll to top